# Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes

> **NCT02914691** · PHASE4 · COMPLETED · sponsor: **Peter Rossing** · enrollment: 40 (actual)

## Conditions studied

- Type 2 Diabetes
- Diabetic Nephropathy

## Interventions

- **DRUG:** Dapagliflozine 10 mg once daily tablet treatment
- **DRUG:** Placebo identical once daily tablet treatment

## Key facts

- **NCT ID:** NCT02914691
- **Lead sponsor:** Peter Rossing
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2017-07-05
- **Final completion:** 2017-07-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914691, "Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02914691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*